Nektar Therapeutics Q3 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Yasmine Rahimi - Piper Sandler - Analyst : Good afternoon team. Thank you so much for all the wonderful updates across the entire pipeline. Really informative, I guess one question. I think a lot of investors are eagerly waiting, the AD and AAV read out and it was really appreciated. The color you gave that enrollment is progressing really well and on track for delivering both data readouts. But could your kind of is there an opportunity to quantify, like where, how close we're getting to bringing both of the studies to finish line? Do you see, I think that could be really helpful. And then two, I think the second question that's most and most often asked is the ability to on a positive data, especially from the ad study, how to extrapolate efficacy and biologically experienced patients. And I apologize for asking two questions. I'll jump back in the queue. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 07, 2024 / 10:00PM, NKTR.OQ - Q3 2024 Nektar Therapeutics Earnings Call

Question: Yasmine Rahimi - Piper Sandler - Analyst : Thank you.

Question: Julian Harrison - BTIG, LLC - Analyst : Hi. Thank you for taking my questions and congratulations on all the recent progress. First, I'm wondering if you have a good sense for when damages could be publicly specified in your ongoing litigation against Eli Lilly.

Question: Julian Harrison - BTIG, LLC - Analyst : Got it understood. And one more, if I may, just on your Phase 2b atopic dermatitis trial, can you remind us of the protocol pertaining to topical steroid use?

Question: Julian Harrison - BTIG, LLC - Analyst : Got it. So all rescu are considered study discontinuations.

Question: Julian Harrison - BTIG, LLC - Analyst : Okay. Great, very. Helpful. Thank you.

Question: Jay Olson - Oppenheimer & Co. Inc. - Analyst : Oh, hey, this is John on the line for Jay. Thanks for taking the question and congrats on progress just on the red pack 80 trial. Since you've been enrolling patient for some time. Now, I'm wondering if you can provide some color on the patient baseline characteristic of seeing, for example, the baseline easy score. And also, if you can share the split between patients who enrolled from US sites versus X US sites, that'd be super helpful. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. NOVEMBER 07, 2024 / 10:00PM, NKTR.OQ - Q3 2024 Nektar Therapeutics Earnings Call

Question: Jay Olson - Oppenheimer & Co. Inc. - Analyst : Got it. Thank you.

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Hey guys, good. Afternoon. Thanks for taking my questions, I guess first one, this data at [EADB] on serum proteo file markers. In ad I believe it was noted that REZPEG reduced expression of serum proteins known to be elevated in AD and I was curious if those expression levels stay reduced. Even after REZPEG therapy was stopped. Kind of trying to get the phenomenon you saw where patients experience sustained benefit even after stopping re peg in the Phase 2b.

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Okay. And.Then for me, if I just didn't, but on the al PIA timing shift from, I think it used to be first half, then mid 25. Now, back half 25. Is that like a delay of getting sites up and running? Is it screen failure or something? What's kind of behind that timing shift?

Question: Jessica Fye - JPMorgan Chase & Co. - Analyst : Thanks.

Question: Andrew Siepker - William Blair - Analyst : Hey, thanks for taking our questions. Just a question on the city poster that's presented today. One is, you looked at the NK cell operations. I'm just wondering if there are any other relevant, cell populations that you looked at that's part one. Part two is really on the control arm. I think Mary, you said that they basically took patients from MD Anderson, in the same, basically the same institution. I'm curious if the limit count pattern is similar to some of the Pacific studies that have been done with AstraZeneca. I'm just curious about the consistency of that trend on the control arm. Thank you.

Question: Andrew Siepker - William Blair - Analyst : Thank you.

Question: Yu He Arthur - H.C. Wainwright & Co., LLC - Analyst : Hey, good afternoon. I just have a quick, quick question regarding the a study design. So after the 36 week maintenance period, does do the patient have the opportunity to receive the treatment continuously during the follow up?

Question: Yu He Arthur - H.C. Wainwright & Co., LLC - Analyst : I see. So which means we can get the data regarding how the off treatment control this control from this study.

Question: Yu He Arthur - H.C. Wainwright & Co., LLC - Analyst : That's exactly right. Okay. Got you. Thanks. Thanks for the call.